{"title":"CD30 - tnf家族的头…或brentuximab vedotin的成功故事","authors":"L. Popović, D. Jovanović, Ðordje Popovic","doi":"10.2298/AOO1301017P","DOIUrl":null,"url":null,"abstract":"Hodgkin lymphoma and anaplastic large cell lymphoma are malignancies that highly express CD30 antigen on the cell surface. Both are generally curable by standard chemotherapy but refractory diseases and relapses are treatment problems. Brentuximab-vedotin is a labeled monoclonal antibody against CD30 and it is approved for the treatment of Hodgkin lymphoma relapsed after autologous stem cell transplantation and for relapsed anaplastic large cell lymphoma. This is the first drug approved for the treatment of Hodgkin lymphoma after 30 years.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1301017P","citationCount":"2","resultStr":"{\"title\":\"CD30 - the head of TNF-family… or a successful story of brentuximab vedotin\",\"authors\":\"L. Popović, D. Jovanović, Ðordje Popovic\",\"doi\":\"10.2298/AOO1301017P\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hodgkin lymphoma and anaplastic large cell lymphoma are malignancies that highly express CD30 antigen on the cell surface. Both are generally curable by standard chemotherapy but refractory diseases and relapses are treatment problems. Brentuximab-vedotin is a labeled monoclonal antibody against CD30 and it is approved for the treatment of Hodgkin lymphoma relapsed after autologous stem cell transplantation and for relapsed anaplastic large cell lymphoma. This is the first drug approved for the treatment of Hodgkin lymphoma after 30 years.\",\"PeriodicalId\":35645,\"journal\":{\"name\":\"Archive of Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2298/AOO1301017P\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archive of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2298/AOO1301017P\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archive of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2298/AOO1301017P","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
CD30 - the head of TNF-family… or a successful story of brentuximab vedotin
Hodgkin lymphoma and anaplastic large cell lymphoma are malignancies that highly express CD30 antigen on the cell surface. Both are generally curable by standard chemotherapy but refractory diseases and relapses are treatment problems. Brentuximab-vedotin is a labeled monoclonal antibody against CD30 and it is approved for the treatment of Hodgkin lymphoma relapsed after autologous stem cell transplantation and for relapsed anaplastic large cell lymphoma. This is the first drug approved for the treatment of Hodgkin lymphoma after 30 years.
期刊介绍：
Archive of Oncology is an international oncology journal that publishes original research, editorials, review articles, case (clinical) reports, and news from oncology (medical, surgical, radiation), experimental oncology, cancer epidemiology, and prevention. Letters are also welcomed. Archive of Oncology is covered by Biomedicina Vojvodina, Biomedicina Serbica, Biomedicina Oncologica, EMBASE/Excerpta Medica, ExtraMED and SCOPUS.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
